Awaiting development: Guidance and quality standards

Showing 161 to 170 of 303

Guidance and quality standards awaiting development
Title	Type
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]	Technology appraisal guidance
Mavorixafor for treating WHIM syndrome [ID3946]	Technology appraisal guidance
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver	Interventional procedures guidance
Mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease ID1237	Technology appraisal guidance
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	Health technology evaluation
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]	Technology appraisal guidance
Middle meningeal artery embolisation for chronic subdural haematomas	Interventional procedures guidance
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over [ID6400]	Technology appraisal guidance
Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 [TSID10730]	Technology appraisal guidance
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]	Technology appraisal guidance